Written by Ι Stock Market Media Group Staff — October 14, 2014
New York, NY – Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an application asking the agency to grant orphan drug status to its Cell-in-a-Box/ifosfamide combination for the rare disease.
The FDA’s orphan drug program designates a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 ...
Read More →OCT